This article focuses on the role of PET/computed tomography in evaluating and managing gastric cancer and colorectal cancer. The authors start with describing the common aspects of imaging with 2-deoxy-2-F-d-glucose, followed by tumor-specific discussions of gastric and colorectal malignancies. Finally, the authors provide a brief overview of non-FDG tracers including their potential clinical applications, and describe future directions in imaging these malignancies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpet.2023.12.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging.
ACS Pharmacol Transl Sci
December 2024
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer, yet early, precise, and noninvasive detection continues to pose a considerable clinical challenge. Glypican-3 (GPC3), a membrane-bound proteoglycan, is markedly overexpressed in most HCC cases, while exhibiting low expression in normal and hepatitis-affected liver tissues. Given its crucial role in malignant transformation and tumor progression, GPC3 emerges as a compelling target for imaging.
View Article and Find Full Text PDFMetabolic markers derived from 18F-FDG PET/CT in suspected recurrent ovarian carcinoma: predictive value for disease burden and prognosis.
Nucl Med Commun
December 2024
Department of Nuclear Medicine.
Objective: This study aims to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in suspected recurrent ovarian carcinoma. Several clinical and PET parameters were assessed to evaluate disease burden and prognosis.
Methods: We did a single-center, retrospective study in patients with suspected recurrent ovarian carcinoma who underwent 18F-FDG PET/CT.
The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy.
Eur Urol Oncol
November 2024
Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Background And Objective: The role of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in addition to magnetic resonance imaging (MRI) for local staging of prostate cancer (PC) has been poorly addressed so far. Our aim was to assess the diagnostic accuracy of PSMA PET/CT and MRI, alone and combined, for detection of extraprostatic extension (EPE) and seminal vesicle invasion (SVI) in PC.
Methods: We conducted a multicenter retrospective study evaluating patients undergoing PSMA PET/CT and MRI before radical prostatectomy.
Activation of the HPA axis does not explain non-responsiveness to GLP-1R agonist treatment in individuals with type 2 diabetes.
Diabetes
November 2024
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Article Synopsis
- * Researchers looked at the effects of GLP-1R agonists on the HPA axis and cortisol levels in individuals with varying responses to the treatment using advanced imaging techniques.
- * Results showed that pituitary GLP-1R expression was present in all participants, and while there were some differences by sex, the study concluded that HPA axis stimulation doesn't explain why some people poorly respond to GLP-1R agonists, suggesting the need for more research.
The Role of Nuclear Medicine in Imaging and Therapy of Prostate Cancer: The State of the Art.
Urol Clin North Am
February 2025
Department of Nuclear Medicine, Sheba Medical Center, Tel-Hashomer, 31 Emek Ha'ela Street, Ramat Gan 52621, Israel; Faculty of Medicine, Tel Aviv University, 35 klachkin Street, Tel Aviv 69978, Israel.
Prostate cancer (PCa) is the second most diagnosed cancer in men. In recent years, nuclear medicine has played an expanding role in diagnosing, staging, monitoring, and treating PCa. Specifically, the introduction of prostate-specific membrane antigen PET/computed tomography has significantly contributed to detecting locoregional and distant disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!